---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021222"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T11:47:15.536969+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023

## Summary
- Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.
- FY 2022 NUPLAZID guidance narrowed to $510-520M from $510-540M; R&D and SG&A guides trimmed.
- FDA accepted trofinetide NDA for Rett syndrome with priority review; PDUFA action date March 12, 2023.
- President Serge Stankovic to retire at year-end; search ongoing. Adora Ndu appointed to Board of Directors.

## SEC filing metadata
- accession: 0000950170-22-021222
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/0000950170-22-021222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/acad-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021222
- JSON: https://secwatch.observer/filing/0000950170-22-021222.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021222.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $130.7 million, net income $(0.17) per common share, EPS $(0.17) per common share. Guidance lowered.
  - Period: third quarter ended September 30, 2022
  - Revenue: $130.7 million
  - Net income: $(0.17) per common share
  - EPS: $(0.17) per common share
  - Guidance: lowered
  - Result: reported results
  source text: Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022. NUPLAZID delivered net sales of $130.7 million in the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/0000950170-22-021222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.